Filing Flows › Janux Therapeutics (JANX) › Q3 2026 › vs Q3 2025
Janux Therapeutics (JANX) Q3 2026 vs Q3 2025 (year over year)
Janux Therapeutics's revenue fell $711K (-7%) from $10.0M in Q3 2025 to $9.3M in Q3 2026.
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.3M | $10.0M | −$711K | -7% |
| Other income, net | $9.7M | $10.9M | −$1.2M | -11% |
| Net loss | $21.6M | $24.3M | −$2.7M | -11% |
| Costs & expenses | $40.5M | $45.3M | −$4.7M | -10% |
| Operating costs | $40.5M | $45.3M | −$4.7M | -10% |
| Research & development | $30.6M | $34.6M | −$4.1M | -12% |
| General & admin | $10.0M | $10.6M | −$640K | -6% |
| Operating cash sources | $34.2M | $22.4M | $11.8M | +53% |
| Depreciation | $458K | $501K | −$43K | -9% |
| Share-based compensation | $8.5M | $9.0M | −$509K | -6% |
| Cash used in operations | $25.2M | $12.9M | $12.3M | +96% |
| Net loss absorbed | $21.6M | $24.3M | −$2.7M | -11% |
| Working capital & other | $12.6M | −$1.9M | $14.5M | — |
Questions
How much did Janux Therapeutics's revenue grow year over year in Q3 2026?
Janux Therapeutics's revenue fell $711K (-7%) from $10.0M in Q3 2025 to $9.3M in Q3 2026.